Letermovir denied as not medically necessary by Humana?

Humana's specific coverage criteria for letermovir are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Letermovir on Medical-Necessity Grounds — and How to Appeal

A medical-necessity denial for letermovir from Humana means the plan has concluded that the clinical documentation submitted does not satisfy the specific criteria in Humana's coverage policy for this drug. For CMV prophylaxis in transplant patients, Humana's criteria typically require documented transplant type, donor/recipient serostatus, and other risk-stratification factors. The denial is usually not a judgment that letermovir is ineffective — it is a documentation gap or a mismatch between how the prescriber described the indication and the exact language in Humana's policy.

## The Federal Legal Framework

• ERISA §503: for employer-sponsored plans, Humana must provide a written denial with the specific criteria not met and must afford a full-and-fair internal review.
• ACA §2719: independent external review is available if the internal appeal fails, generally within approximately four months of denial. An expedited track applies when the patient's post-transplant prophylaxis window is time-sensitive.

## Concrete Appeal Steps and Timeline

1. Get the denial in writing: Humana must identify every criterion not met — request this if not fully stated. 2. Peer-to-peer review: the transplant prescriber should call Humana's medical director before or during the appeal to walk through the clinical picture directly. 3. First-level internal appeal: file within the timeframe in the denial letter (typically 180 days). Humana must respond within 30 days for pre-service, 60 days for retrospective, and 72 hours for expedited. 4. Second-level internal review if offered. 5. External review: file with the IRO if internal appeals are exhausted; medical-necessity denials for FDA-approved antivirals in transplant prophylaxis are frequently reversed when documentation is complete.

## Documentation to Gather

• Transplant documentation: operative or discharge records confirming transplant type, date, and donor source.
• CMV serostatus: laboratory reports for both donor and recipient CMV IgG serostatus — this is often the single most important missing piece in a letermovir denial.
• Immunosuppression regimen: current medication list showing the immunosuppression protocol, establishing the degree of immune compromise.
• Risk-stratification chart note: a note from the transplant team documenting CMV risk category per the applicable transplant guidelines and explaining why prophylaxis is the chosen strategy over pre-emptive therapy.
• Prescriber medical-necessity letter: a letter from the transplant physician or transplant infectious disease specialist that maps each of Humana's coverage criteria to a specific finding in the chart, referencing the relevant transplant society guideline organization for support.
• Humana's coverage policy: obtain Humana's current letermovir medical policy before writing the appeal so every criterion is addressed point by point.

## Criteria-Mapping Structure

Create a table in the appeal letter. Left column: each requirement from Humana's letermovir coverage policy. Right column: the specific chart finding, lab result date, or clinical note that satisfies it. Do not leave any criterion unanswered — an unanswered criterion is a denial waiting to happen. If a criterion is met but the documentation was not included in the original prior-authorization request, include it now and note when it was established in the medical record. A complete criteria-matched appeal with a peer-to-peer call resolves the large majority of medical-necessity denials for letermovir.